Literature DB >> 1317548

Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector.

G W Wilkinson1, A Akrigg.   

Abstract

A defective adenovirus (Ad) type 5 E1- vector has been combined with the powerful constitutive cytomegalovirus (CMV) major immediate early (IE) promoter to produce a novel eukaryotic expression system. The Ad vector can replicate to high titres in 293 cells and then be used to infect a wide variety of non-permissive cell types. The Escherichia coli lacZ and CMV IE1 genes have been cloned to generate the Ad recombinants RAd35 and RAd31 respectively. In human fibroblasts infected with RAd35 beta-galactosidase (beta-gal) expression could be detected in virtually 100% of target cells, there was no detectable transcription from the Ad genome and extremely high levels of expression could be achieved with beta-gal representing the predominant cytoplasmic cellular protein. Additionally, a number of agents, including the CMV IE1 gene product (in RAd31) and forskolin, significantly enhanced expression from RAd35-infected human fibroblasts. Lower levels of constitutive beta-gal expression were obtained in RAd35-infected HeLa cells but again expression could be enhanced (up to 60 fold) by chemical inducing agents. Expression from the IE promoter in the Ad vector could be repressed by coinfection with CMV.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317548      PMCID: PMC312336          DOI: 10.1093/nar/20.9.2233

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  31 in total

1.  The use of engineered E1A genes to transactivate the hCMV-MIE promoter in permanent CHO cell lines.

Authors:  M I Cockett; C R Bebbington; G T Yarranton
Journal:  Nucleic Acids Res       Date:  1991-01-25       Impact factor: 16.971

2.  A cis-acting element in the major immediate-early (IE) promoter of human cytomegalovirus is required for negative regulation by IE2.

Authors:  B Liu; T W Hermiston; M F Stinski
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

3.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

4.  The IE2 gene products of human cytomegalovirus specifically down-regulate expression from the major immediate-early promoter through a target sequence located near the cap site.

Authors:  M C Pizzorno; G S Hayward
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

5.  Cloning of the herpes simplex virus ICP4 gene in an adenovirus vector: effects on adenovirus gene expression and replication.

Authors:  R Spessot; K Inchley; T M Hupel; S Bacchetti
Journal:  Virology       Date:  1989-02       Impact factor: 3.616

6.  The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements.

Authors:  Y N Chang; S Crawford; J Stall; D R Rawlins; K T Jeang; G S Hayward
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

7.  Cell type-specific induction of the major immediate early enhancer of human cytomegalovirus by cyclic AMP.

Authors:  T Stamminger; H Fickenscher; B Fleckenstein
Journal:  J Gen Virol       Date:  1990-01       Impact factor: 3.891

8.  The human cytomegalovirus immediate early enhancer-promoter is responsive to activation by the adenovirus-5 13S E1A gene.

Authors:  D M Olive; W al-Mulla; M Simsek; S Zarban; W al-Nakib
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

9.  Human cytomegalovirus ie2 negatively regulates alpha gene expression via a short target sequence near the transcription start site.

Authors:  J M Cherrington; E L Khoury; E S Mocarski
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

10.  In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium.

Authors:  M A Rosenfeld; K Yoshimura; B C Trapnell; K Yoneyama; E R Rosenthal; W Dalemans; M Fukayama; J Bargon; L E Stier; L Stratford-Perricaudet
Journal:  Cell       Date:  1992-01-10       Impact factor: 41.582

View more
  56 in total

1.  Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases.

Authors:  C E Thomas; G Schiedner; S Kochanek; M G Castro; P R Löwenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 2.  The promise of gene therapy in gastrointestinal and liver diseases.

Authors:  J Prieto; M Herraiz; B Sangro; C Qian; G Mazzolini; I Melero; J Ruiz
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

3.  Immune-mediated loss of transgene expression from virally transduced brain cells is irreversible, mediated by IFNγ, perforin, and TNFα, and due to the elimination of transduced cells.

Authors:  Jeffrey M Zirger; Mariana Puntel; Josee Bergeron; Mia Wibowo; Rameen Moridzadeh; Niyati Bondale; Carlos Barcia; Kurt M Kroeger; Chunyan Liu; Maria G Castro; Pedro R Lowenstein
Journal:  Mol Ther       Date:  2012-01-10       Impact factor: 11.454

4.  Gene delivery into neuronal and glial cells by using a replication-deficient adenovirus vector: prospects for neurological gene therapy.

Authors:  S Sivasubramaniam; A Fooks; J Lee; G Stacey; A Jennings
Journal:  Cytotechnology       Date:  1997-09       Impact factor: 2.058

5.  Rapid upregulation of interferon-regulated and chemokine mRNAs upon injection of 108 international units, but not lower doses, of adenoviral vectors into the brain.

Authors:  Jeffrey M Zirger; Carlos Barcia; Chunyan Liu; Mariana Puntel; Ngan Mitchell; Iain Campbell; Maria Castro; Pedro R Lowenstein
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  Measles virus-induced immune suppression in the cotton rat (Sigmodon hispidus) model depends on viral glycoproteins.

Authors:  S Niewiesk; I Eisenhuth; A Fooks; J C Clegg; J J Schnorr; S Schneider-Schaulies; V ter Meulen
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

7.  Human cytomegalovirus IE1-72 activates ataxia telangiectasia mutated kinase and a p53/p21-mediated growth arrest response.

Authors:  Jonathan P Castillo; Fiona M Frame; Harry A Rogoff; Mary T Pickering; Andrew D Yurochko; Timothy F Kowalik
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.

Authors:  Sumia Ali; Gwendalyn D King; James F Curtin; Marianela Candolfi; Weidong Xiong; Chunyan Liu; Mariana Puntel; Queng Cheng; Jesus Prieto; Antoni Ribas; Jerzy Kupiec-Weglinski; Nico van Rooijen; Hans Lassmann; Pedro R Lowenstein; Maria G Castro
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

9.  Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1.

Authors:  Kurt J Sales; Vivien Grant; Ian H Cook; David Maldonado-Pérez; Richard A Anderson; Alistair R W Williams; Henry N Jabbour
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

10.  In vitro and in vivo analysis of expression cassettes designed for vascular gene transfer.

Authors:  S J White; E D Papadakis; C A Rogers; J L Johnson; E A L Biessen; A C Newby
Journal:  Gene Ther       Date:  2007-11-08       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.